MedTrace Logo

USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19

NCT04425850 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 229

Last updated 2020-10-19

Study results available
· View outcomes & findings →

Summary

Estimation of the prevalence and contagiousness of undocumented novel coronavirus infections is critical for understanding the overall prevalence and pandemic potential of this disease.

It is estimated that 86% of all infections were undocumented \[95% credible interval (CI): 82-90%\] before the 23 January 2020 travel restrictions. The transmission rate of undocumented infections per person was 55% the transmission rate of documented infections (95% CI: 46-62%), yet, because of their greater numbers, undocumented infections were the source of 79% of the documented cases.

Ivermectin + Carrageenan, taking advantage of their virucidal effects, are aimed at reducing the contagion.

Conditions

  • Covid19

Interventions

COMBINATION_PRODUCT

Iota carrageenan nasal spray and Ivermectin oral drops (used as buccal drops)

Topical application in the nose and oral cavity

Sponsors & Collaborators

  • Eurnekian Public Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-06-01
Primary Completion
2020-08-10
Completion
2020-08-10

Countries

  • Argentina

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04425850 on ClinicalTrials.gov